Could a common diabetes drug slash heart risks in hypertension?
NCT ID NCT06804161
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a daily SGLT2 inhibitor pill can reduce heart attacks, strokes, and other cardiovascular events in 3,000 adults aged 60+ with high blood pressure and a history of heart or blood vessel problems. Participants will receive either the drug or a placebo for several years. The goal is to see if this drug, already used for diabetes and heart failure, can offer extra protection for people with hypertension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT2 inhibitor (a type of diabetes drug that also lowers blood pressure)
What this could lead to
If successful, this could lead to a new standard treatment to prevent heart attacks and strokes in people with high blood pressure.
What could go wrong
This is a large phase 3 trial, but SGLT2 inhibitors are already used for diabetes and heart failure, so the added benefit for hypertension alone may be modest. Side effects like dehydration or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universität zu Lübeck
RECRUITINGLübeck, Schleswig-Holstein, 23538, Germany
Contact
Contact